Aytu BioScience Inc (AYTU)
NASDAQ:AYTU
Top Page
Aytu BioScience
(NASDAQ:AYTU)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.50
▼(-1.96% Downside)
Action:ReiteratedDate:02/05/26
The score is held down primarily by weak financial performance (revenue contraction, continuing losses, negative free cash flow, and rising leverage). Technicals add a near-term bearish tilt (below 20/50-day averages with weak momentum). Offsetting factors are a moderately constructive earnings-call outlook driven by early EXXUA launch traction and spend discipline, while valuation remains constrained due to negative earnings and no dividend.
Positive Factors
First‑in‑class EXXUA commercial launch
EXXUA's first‑in‑class status and Phase 3 support create a durable product differentiator. Early commercial traction (>100 prescribers, multi-channel promotion) and a targeted safety/efficacy profile can sustain physician adoption, diversify revenue streams, and reduce reliance on legacy ADHD sales if uptake and payer access continue to progress.
Negative Factors
Eroding equity and rising leverage
Declining stockholders' equity and a debt-to-equity ratio above 1x materially weaken balance-sheet resilience. Higher leverage limits strategic flexibility, increases refinancing and liquidity risk, and raises the likelihood management will need dilutive financing or operational retrenchment if revenue or launch cadence disappoints, a durable capital-structure constraint.
Read all positive and negative factors
Positive Factors
Negative Factors
First‑in‑class EXXUA commercial launch
EXXUA's first‑in‑class status and Phase 3 support create a durable product differentiator. Early commercial traction (>100 prescribers, multi-channel promotion) and a targeted safety/efficacy profile can sustain physician adoption, diversify revenue streams, and reduce reliance on legacy ADHD sales if uptake and payer access continue to progress.
Read all positive factors
Aytu BioScience (AYTU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.37M
Dividend YieldN/A
Average Volume (3M)314.73K
Price to Earnings (P/E)―
Beta (1Y)1.73
Revenue Growth-15.61%
EPS Growth-68.96%
CountryUS
Employees102
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.05
Shares Outstanding10,733,208
10 Day Avg. Volume289,104
30 Day Avg. Volume314,725
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.72
Price to Sales (P/S)0.21
P/FCF Ratio-2.65
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue0.23
Enterprise Value/Gross Profit0.35
Enterprise Value/Ebitda-0.83
Forecast
1Y Price Target
$9.67Price Target Upside279.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.19
Revenue Forecast (FY)$56.93M
Aytu BioScience Business Overview & Revenue Model
Company Description
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of a...
How the Company Makes Money
Aytu generates revenue primarily from net product sales of its prescription pharmaceuticals in the United States. The company’s revenue model is typical of a commercial-stage specialty pharma business: it sells branded products to customers such a...
Aytu BioScience Key Performance Indicators (KPIs)
Any
Revenue by Product
Shows how much revenue each product contributes, highlighting best-sellers and potential areas for growth or concern based on product performance.
Shows how much revenue each product contributes, highlighting best-sellers and potential areas for growth or concern based on product performance.
Data provided by:
The Fly
The FlyAytu BioScience Earnings Call Summary
Earnings Call Date:Feb 03, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Neutral
The call presents a balanced picture: strong strategic and commercial progress with the ExuA launch (first-in-class therapy, >100 prescribers, RxConnect-enabled access, and supply readiness) and resilient ADHD performance are meaningful positives. However, near-term financials show declines in net revenue, gross margin pressure (partly from a $600k write-down), higher operating spend for launch, a negative adjusted EBITDA, and a substantial reported net loss driven largely by an $8.2M non-cash derivative warrant loss. Early ExuA metrics are encouraging but limited by short launch duration and weather-related field disruption; cash levels are adequate but have declined modestly. Overall, positives around product launch and access are counterbalanced by near-term financial headwinds and potential generic risk.Positive Updates
Commercial Launch of ExuA — First-in-Class 5-HT1A Agonist
Launched ExuA (first and only FDA-approved 5-HT1A agonist for MDD); commercial launch underway with early commercial activity and multi-channel promotional plan.
Negative Updates
Total Net Revenue Decline
Net revenue of $15.2M for the quarter vs $16.2M prior year, a decline of $1.0M (≈ -6.2% year-over-year).
Read all updates
Q2-2026 Updates
Positive
Negative
Commercial Launch of ExuA — First-in-Class 5-HT1A Agonist
Launched ExuA (first and only FDA-approved 5-HT1A agonist for MDD); commercial launch underway with early commercial activity and multi-channel promotional plan.
Read all positive updates
Company Guidance
The company guided that ExuA commercialization will begin with a small initial net-revenue ramp in the March quarter—scripts are expected to grow ahead of net revenue because RxConnect guarantees month‑1 and month‑2 supplies at no cost for commercially insured patients (those guarantees begin to be removed in June as month‑3 refills occur)—and advised modelers to assume gross margins in the mid‑ to high‑60% range (management cites a simplified ~31% COGS / ~69% gross contribution margin reflecting a 28% royalty plus true‑up). Launch spend was trimmed from an initial $10.0M plan to under $8.0M (about $3.0M of which are one‑time items), near‑term OpEx in March is expected to be roughly $4.0M–$5.0M (excluding D&A), and the company expects to exit the fiscal year at an ~ $11.6M quarterly normalized OpEx run‑rate (with ~ $0.5M in non‑cash items). Management said breakeven is around $17.3M of net revenue per quarter (all‑in) and cash breakeven about $16.6M/quarter; cash was $30.0M at 12/31/2025. For context, Q2 net revenue was $15.2M (ADHD $13.2M; pediatric $1.7M), gross margin was 63.5% (67.4% excluding a ~$600k inventory write‑down), adjusted EBITDA was –$0.8M, net loss was $10.6M (–$1.05/share) driven in part by an $8.2M derivative warrant liability loss, and the share count footprint is ~10.7M common shares plus 8.8M prefunded warrants (≈19.5M effective).Aytu BioScience Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
38
Negative
Cash Flow
27
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.64M | 66.38M | 65.18M | 107.40M | 96.67M | 65.63M |
| Gross Profit | 41.34M | 45.83M | 49.05M | 66.63M | 50.28M | 29.20M |
| EBITDA | -17.24M | -4.67M | 1.41M | -3.27M | -27.96M | -29.04M |
| Net Income | -24.44M | -13.56M | -15.84M | -17.05M | -108.78M | -58.29M |
Balance Sheet | ||||||
| Total Assets | 122.00M | 124.18M | 118.86M | 137.84M | 137.62M | 265.67M |
| Cash, Cash Equivalents and Short-Term Investments | 30.02M | 30.95M | 20.01M | 22.98M | 19.36M | 49.65M |
| Total Debt | 23.07M | 22.94M | 16.42M | 30.43M | 18.19M | 30.97M |
| Total Liabilities | 107.80M | 105.21M | 91.14M | 98.48M | 93.31M | 128.10M |
| Stockholders Equity | 14.20M | 18.97M | 27.72M | 39.36M | 44.31M | 137.57M |
Cash Flow | ||||||
| Free Cash Flow | -698.00K | -5.17M | -1.72M | -5.13M | -28.82M | -25.96M |
| Operating Cash Flow | -595.00K | -1.94M | -1.39M | -5.13M | -28.82M | -25.96M |
| Investing Cash Flow | -3.10M | -2.56M | -329.00K | -117.00K | -3.25M | -2.78M |
| Financing Cash Flow | 13.32M | 15.44M | -1.26M | 8.87M | 1.53M | 30.31M |
Aytu BioScience Technical Analysis
Neutral
2.55
Price Trends
2.51
Positive
2.47
Positive
2.37
Positive
Market Momentum
0.02
Positive
46.75
Neutral
30.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AYTU, the sentiment is Neutral. The current price of 2.55 is below the 20-day moving average (MA) of 2.63, above the 50-day MA of 2.51, and above the 200-day MA of 2.37, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 46.75 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AYTU.
Aytu BioScience Risk Analysis
Aytu BioScience disclosed 59 risk factors in its most recent earnings report. Aytu BioScience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aytu BioScience Peers Comparison
UnderperformOutperform
Sector (51)
AYTU
Aytu BioScience
2.55
1.55
155.00%
TXMD
TherapeuticsMD
2.07
1.04
100.97%
COSM
Cosmos Holdings
0.30
-0.04
-12.28%
GELS
Gelteq Limited
0.70
-0.23
-25.16%
Aytu BioScience Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Aytu BioScience Amends Warrants, Modifying Security Holder Rights
Neutral
Apr 2, 2026
Aytu BioScience reported that it amended certain outstanding warrants in a transaction structured as a private exchange of securities rather than a registered public offering under the Securities Act of 1933. The company relied on exemptions from ...
Business Operations and StrategyProduct-Related Announcements
Aytu BioPharma Highlights EXXUA Opportunity at Investor Day
Positive
Jan 20, 2026
On January 20, 2026, Aytu BioPharma held an Investor Day in New York City, with in-person and webcast participation, to spotlight the commercial and clinical opportunity for EXXUA (gepirone) extended-release tablets, which had been launched the pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.